An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Editorial by Manuel Marfil (on behalf of GIBI230: Research Group on Biomedical Imaging of Instituto de Investigación Sanitaria La Fe, HULAFE) Grounded in Evidence: building trust through Clinical Validation After more than three years of the ProCAncer-I, an EU funded...
Jurgita Usinskiene (dr. chief radiologist), Kristina Slidevska (radiation oncologist), Audrius Untanas (radiologist); National Cancer Institute, Vilnius, Lithuania Clinical Challenge: Artificial Intelligence-Powered Prediction of Prostate Cancer Treatment Response...
Βy Prof. Daniele Regge, Chief of the Radiology Unit and Simone Mazzetti; Candiolo Cancer Institute, Torino-Italy Presentation of the AI-QUAL study Magnetic resonance imaging (MRI) has become an essential tool in the diagnosis and management of patients with...
Interview with Dr. Kai Vilanova, Director MRI Clínica Girona, Coordinator Radiology, Faculty of Medicine, University of Girona. Director School of MRI-ESMRMB (IDIBGI) and Prof. Dow-Mu Koh, MD., M.R.C.P., F.R.C.R. Professor in Functional Cancer Imaging, Consultant...
Agios Savvas (St Savvas) The Hellenic Cancer Institute (HCI) was founded in 1935 by the "Christian Social Union". One of the first works of HCI was the establishment and operation of the "Agios Savvas" hospital (Geniko Antikarkiniko Ogkologiko Nosokomeio...
The Institut Paoli-Calmettes (IPC) Cancer Center Based in Marseille, The Institut Paoli-Calmettes (IPC) Cancer Center has been certified Comprehensive Cancer Center by OECI (Organisation of European Cancer Institutes) in June 2019 and then in June 2024. The IPC...
Newsletter #7 Contents
Great news!Our paper "Data infrastructures for AI in medical imaging: a report on the experiences of five EU projects" published in European Radiology Experimental, has been the Fourth most cited article for the Impact Factor 2024 calculation. A short award ceremony...
An international and multidisciplinary team, led by researchers from the Champalimaud Foundation, in Lisbon, has developed an artificial intelligence algorithm that improves the reliability of prostate cancer detection based solely on magnetic resonance imaging...
Prostate cancer is the second most commonly diagnosed cancer in men. Conventional screening relies on prostate specific antigen (PSA) levels in the blood, which can indicate prostate abnormalities but lacks specificity. Clinical examination and ultrasound also have...
The ProCAncer-I project aims to revolutionize prostate cancer diagnosis and treatment through the power of artificial intelligence and advanced imaging. By creating a large, federated database of prostate MRI scans and clinical data, the project enables the...